New antibody-drug tech licensed by Asahi Kasei targets cancer cells precisely
- Posted on May 27, 2026
- By Google News
- 0 Views
- 1 min read
New antibody-drug tech licensed by Asahi Kasei targets cancer cells precisely
Dual-payload ADCs enable precise drug-to-antibody control, as Asahi Kasei works toward commercialization, potential sub-licensing and research.